These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 8243083)

  • 21. Coadministration of oral levofloxacin with agents that impair its absorption: potential impact on emergence of resistance.
    Quain RD; Barton TD; Fishman NO; Weiner MG; Lautenbach E
    Int J Antimicrob Agents; 2005 Oct; 26(4):327-30. PubMed ID: 16154325
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Treatment of pneumonia: new strategies for changing pathogens.
    Ashby BL
    Clin Ther; 1991; 13(5):637-50. PubMed ID: 1799921
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Therapeutic efficacy of ofloxacin, ciprofloxacin and NY-198 in experimentally infected normal and alloxan-induced diabetic mice.
    Obana Y; Nishino T
    Drugs Exp Clin Res; 1988; 14(5):327-31. PubMed ID: 3219995
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Efficacy of lomefloxacin and ofloxacin in complex therapy of infections in patients with burns].
    Krutikov MG; Alekseev AA; Bobrovnikov AE; Grishina IA; Elagina LV; Izotova GN; Iakovlev VP
    Antibiot Khimioter; 1998; 43(10):27-31. PubMed ID: 9825107
    [TBL] [Abstract][Full Text] [Related]  

  • 25. In vitro activity of gemifloxacin and contemporary oral antimicrobial agents against 27247 Gram-positive and Gram-negative aerobic isolates: a global surveillance study.
    Bouchillon SK; Hoban DJ; Johnson JL; Johnson BM; Butler DL; Saunders KA; Miller LA; Poupard JA
    Int J Antimicrob Agents; 2004 Feb; 23(2):181-96. PubMed ID: 15013045
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Nonfermentative gram-negative bacilli in cancer patients: increasing frequency of infection and antimicrobial susceptibility of clinical isolates to fluoroquinolones.
    Rolston KV; Kontoyiannis DP; Yadegarynia D; Raad II
    Diagn Microbiol Infect Dis; 2005 Mar; 51(3):215-8. PubMed ID: 15766609
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Respiratory fluoroquinolones in the treatment of exacerbations of chronic obstructive lung disease].
    Shmelev EI
    Probl Tuberk Bolezn Legk; 2004; (12):13-6. PubMed ID: 15719658
    [No Abstract]   [Full Text] [Related]  

  • 28. [Role of oral fluoroquinolones in patients with respiratory diseases].
    Ishida T
    Kekkaku; 2003 Oct; 78(10):653-9. PubMed ID: 14621574
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Maxaquin and ciprofloxacin in the treatment of complicated and recurrent urinary infections in adults].
    Savitskaia KI; Trapeznikova MF; Nekhorosheva AG; Solodilova OE; Nasonov VN; Dutov VV; Kalinin VN; Shanina AG; Rusanova EV
    Klin Med (Mosk); 1994; 72(2):38-42. PubMed ID: 8015241
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Coadministration of oral levofloxacin with agents that impair absorption: impact on antibiotic resistance.
    Cohen KA; Lautenbach E; Weiner MG; Synnestvedt M; Gasink LB
    Infect Control Hosp Epidemiol; 2008 Oct; 29(10):975-7. PubMed ID: 18808343
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The pharmacokinetics of oral quinolones (norfloxacin, ciprofloxacin, ofloxacin).
    Alestig K
    Scand J Infect Dis Suppl; 1990; 68():19-22. PubMed ID: 2218417
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Efficacy of lomefloxacin in treatment of nonspecific inflammatory diseases and in prophylaxis of postoperative complications in urology].
    Derevianko II; Khodyreva LA; Avdoshin VL; Andriukhin MI; Gabliia MIu
    Antibiot Khimioter; 1998; 43(10):36-41. PubMed ID: 9825109
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Sequential intravenous/oral ciprofloxacin in the treatment of severe multiresistant gram-negative infections.
    Chayakul P; Krisanapan S; Kalnauwakul S
    J Med Assoc Thai; 1993 Jan; 76(1):35-40. PubMed ID: 8228692
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ofloxacin in urinary tract infections.
    Kromann-Andersen B; Krøyer Nielsen K
    Scand J Infect Dis Suppl; 1990; 68():35-40. PubMed ID: 2218420
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Norfloxacin, ciprofloxacin, and ofloxacin: current clinical roles.
    Hooper DC; Wolfson JS
    Curr Clin Top Infect Dis; 1989; 10():194-240. PubMed ID: 2679694
    [No Abstract]   [Full Text] [Related]  

  • 36. [Use of fluoroquinolones in rheumatology].
    Belov BS; Shubin SV; Nasonova VA; Soldatova SI; Tarasova GM; Urumova MM; Ushakova MA; Anan'eva LP
    Vestn Ross Akad Med Nauk; 1996; (12):12-5. PubMed ID: 9102072
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Levofloxacin (Tavanic) in the treatment of corneal ulcers].
    Maĭchuk IuF
    Antibiot Khimioter; 2003; 48(6):16-9. PubMed ID: 14558414
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Biochemical, pharmacokinetic and bacteriologic properties of ofloxacin].
    Doco-Lecompte T
    Acta Leprol; 1991; 7(4):315-9. PubMed ID: 1950439
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [A review of clinical studies on the efficacy and tolerance of intravenous ciprofloxacin].
    Memoli M
    Recenti Prog Med; 1992 Jan; 83(1):27-34. PubMed ID: 1561480
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Oral fluoroquinolone therapy results in drug adsorption on ureteral stents and prevention of biofilm formation.
    Reid G; Habash M; Vachon D; Denstedt J; Riddell J; Beheshti M
    Int J Antimicrob Agents; 2001 Apr; 17(4):317-9; discussion 319-20. PubMed ID: 11295415
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.